Lantheus Holdings 新闻与活动
在场
是其中之一......
Lantheus Holdings 是一家在股票代码 LNTH (US) 下上市的公司。
Lantheus Holdings 在 2 个国家有直接业务。
他们在：
涉及Lantheus Holdings的并购和融资。
高管
查看带有其 45 名主要高管的组织结构图
Lantheus Holdings 搜索最多的简介
- Brian Markison, Chief Executive Officer and Director (until Dec 31...
- Gary Pruden, Director
- Mary Anne Heino, Executive Chairman of the Board and Interim Chief...
高管在Lantheus Holdings变化
- Paul Blanchfield, President , 已经离开公司 (新闻发布的2025十一月11号).
- Brian Markison, Chief Executive Officer and Director, 将于 202512月31 退休 (新闻发布的2025十一月7号).
- Mary Anne Heino 曾任 Chairman of the Board, 现任 Executive Chairman of the Board and Interim Chief Executive Officer (新闻发布的2025十一月7号).
创建提醒
跟踪 Lantheus Holdings 的高管变动
药店
Lantheus Holdings 拥有 1,861 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- Mitsubishi Tanabe Pharma Germany将在Dec 1, 2025将其名称改为Tanabe Pharma。 (公布2025十一月12号).
- Mitsubishi Tanabe Pharma Europe将在Dec 1, 2025将其名称改为Tanabe Pharma Europe。 (公布2025十一月12号).
- Mitsubishi Tanabe Pharma Canada将在Dec 1, 2025将其名称改为Tanabe Pharma Canada。 (公布2025十一月12号).
药店 行业的其他推荐联系人
消息
Lantheus Holdings 的最新新闻稿
- Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update | Lantheus Holdings, Inc.
- Lantheus Announces Leadership Transition Plan | Lantheus Holdings, Inc.
- Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease | Lantheus Holdings, Inc.
- Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) | Lantheus Holdings, Inc.
- Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time | Lantheus Holdings, Inc.
- Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan | Lantheus Holdings, Inc.
- Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference | Lantheus Holdings, Inc.
- Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent | Lantheus Holdings, Inc.
- Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update | Lantheus Holdings, Inc.
- Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time | Lantheus Holdings, Inc.
- View more press releases Close
